ArticleClinicoEconomics and outcomes research : CEOR2025

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer.

Wesley Furnback et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.